Email not displaying correctly? View it in your browser

 
First patients recruited in Phase I study on Oxaborole SCYX-7158 for HAT
 
DNDi has commenced a Phase I clinical trial for Oxaborole SCYX-7158 to treat human African trypanosomiasis (or sleeping sickness) for stage 1 and stage 2 of the disease.  Dr Nathalie Strub, Medical Director at DNDi, talks about DNDi’s drug development pipeline for HAT and this new clinical trial.
 Read more
Listen to Podcast    
 ©      Benoit Marquet/DNDi
DNDi secures EUR 2 million from Wellcome Trust for Chagas drug development
 
DNDi has received a EUR 2 Million Strategic Translation Award from the Wellcome Trust to develop the azole compound E1224, a promising drug to treat Chagas disease being tested in Bolivia.
 Read more

17th Meeting of the LEAP Platform in Uganda  

The 17th Meeting of the Leishmaniasis East Africa Platform (LEAP) was organized in Kampala.  An overview of the state of affairs of paromomycin registration in LEAP countries, which is essential to implementation of SSG&PM as first-line treatment for kala-azar, was presented. Dr. Joseph Olobo, Associate Professor, Makerere University, talks about paromomycin registration in Uganda and use of SSG&PM.
Listen to Podcast   
 
International ethical review of DNDi fexinidazole study protocols for sleeping sickness
Chaired by the Société Française et Francophone d’Ethique Médicale (SFFEM), this recent review brought together - the first time ever - the Ethics Department of WHO and representatives of ethics committees from six African countries with the aim of reducing duplication of efforts.
Read more

Publication: "Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it?"

Lucio H. Freitas-Junior, Eric Chatelain, Helena Andrade Kim, Jair L. Siqueira-Neto. International Journal for Parasitology: Drugs and Drug Resistance, Volume 2, December 2012 ..
Read more